Patrick Baeuerle (born 24 November 1957) is a German-based molecular biologist, immunologist, professor and a biopharmaceutical entrepreneur.
Baeuerle is known for his work on tyrosine sulfation of proteins,[1] transcription factor NF-kappaB,[2] and the development of bispecific T-cell engaging antibodies for therapy of cancer.
[6] Between 1996 and 2015, he served as head of drug discovery at Tularik Inc.,[7][8] as chief scientific officer at Micromet Inc.,[9][10] and as a vice president research for Amgen Inc.[11] in Munich, Germany.
[11][13] In 1987, Baeuerle showed that tyrosine sulfation is a frequent modification of secretory proteins that is added in the trans-Golgi compartment.
[18][19] Baeuerle lead the development of BiTE antibody Blincyto® (blinatumomab; AMG 103)[20] which is approved by the US FDA for treatment of relapsed/refractory acute lymphoblastic leukemia.